Syros Pharmaceuticals Down 4.24% To $5.99 After Earnings

reported that it broke-even during the quarter.



The stock is down 4.24% to $5.99 after the report.

Syros Pharmaceuticals's profit margins maintained as both earnings and revenue declined at the same pace.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

Trading in the five days leading up to the report earned Syros Pharmaceuticals a Bullish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 72. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.

Syros Pharmaceuticals Inc is a biopharmaceutical company engaged in a non-coding regulatory region of the genome controlling the activation and repression of genes. It is primarily involved in the segments of the pharmaceutical, biotechnology, and other related markets that address gene control and cancer. The Company operates only in the United States.